Related Experiment Video
Updated: Jun 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting
Yagya Ahlawat1, Heng Jiang2, Delong Liu3
1Division of Hematology and Oncology, Westchester Medical Center, New York Medical College, Valhalla, NY, 10595, USA.
Abstract:
Luspatercept, an erythroid maturation agent, and imetelstat, a first-in-class telomerase inhibitor, have expanded the therapeutic landscape for patients with myelodysplastic neoplasms (MDS). Recent data presented at the 2025 American Society of Hematology (ASH) Annual Meeting further clarify their evolving clinical roles. New analyses evaluated the real-world use of luspatercept in patients with lower-risk MDS (LR-MDS), while additional studies characterized the efficacy and outcomes associated with imetelstat in transfusion-dependent (TD) LR-MDS and in advanced MDS or acute myeloid leukemia following hypomethylating agent failure. We summarized the latest updates on luspatercept and imetelstat for MDS from the 2025 ASH Annual Meeting.
Related Concept Videos
iPS Cell Differentiation
Treatment Resistent Cancers
Mesenchymal Stem Cells
